What is Leerink Partnrs’ Estimate for BBIO Q1 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for BridgeBio Pharma in a report released on Monday, February 24th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($0.73) for the quarter. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.40) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $0.40 EPS, FY2028 earnings at $3.10 EPS and FY2029 earnings at $4.85 EPS.

Several other research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Scotiabank upped their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Evercore ISI lifted their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Citigroup raised their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $51.67.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO opened at $34.35 on Wednesday. BridgeBio Pharma has a one year low of $21.62 and a one year high of $39.47. The company has a market cap of $6.53 billion, a price-to-earnings ratio of -12.05 and a beta of 1.07. The firm has a 50 day simple moving average of $32.20 and a 200 day simple moving average of $28.13.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million.

Insider Buying and Selling

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 68,000 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the transaction, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $3,402,477.82. This represents a 42.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares of the company’s stock, valued at $769,732,587.50. This represents a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,496,239 shares of company stock valued at $122,612,036 over the last quarter. Insiders own 24.66% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Polar Asset Management Partners Inc. acquired a new position in shares of BridgeBio Pharma during the third quarter valued at about $1,286,000. First Turn Management LLC bought a new stake in BridgeBio Pharma in the 3rd quarter valued at about $10,178,000. Janus Henderson Group PLC raised its stake in BridgeBio Pharma by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after buying an additional 505,481 shares during the period. Intech Investment Management LLC bought a new position in BridgeBio Pharma in the third quarter worth approximately $1,136,000. Finally, Principal Financial Group Inc. boosted its holdings in BridgeBio Pharma by 1.8% in the third quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock worth $29,155,000 after acquiring an additional 19,978 shares in the last quarter. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.